Shots:

• Health Canada’s marketing authorization transfer of Otezla from Celgene follows Amgen’s acquisition of the global rights of Otezla completed in Nov’2019
• The addition of Otezla bolster Amgen’s portfolio of innovative biologics and biosimilar products and complements its expertise in mod. to sev. PsO and active PsA
• Otezla is a selective PDE4 inhibitor- inhibiting the production of TNF-alpha from human rheumatoid synovial cells and is an approved therapy for mod. to sev. PsO who are candidates for phototherapy or systemic therapy and for patients with active PsA with inadequate response to DMARD

Click here ­to­ read full press release/ article | Ref: Newswire Canada | Image: StraitTimes